APA (7th ed.) Citation

De Vita, S., Quartuccio, L., Seror, R., Salvin, S., Ravaud, P., Fabris, M., . . . Mariette, X. (2015). Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: The BELISS open-label phase II study. Rheumatology (Oxford, England), 54(12), 2249. https://doi.org/10.1093/rheumatology/kev257

Chicago Style (17th ed.) Citation

De Vita, Salvatore, et al. "Efficacy and Safety of Belimumab Given for 12 Months in Primary Sjögren's Syndrome: The BELISS Open-label Phase II Study." Rheumatology (Oxford, England) 54, no. 12 (2015): 2249. https://doi.org/10.1093/rheumatology/kev257.

MLA (9th ed.) Citation

De Vita, Salvatore, et al. "Efficacy and Safety of Belimumab Given for 12 Months in Primary Sjögren's Syndrome: The BELISS Open-label Phase II Study." Rheumatology (Oxford, England), vol. 54, no. 12, 2015, p. 2249, https://doi.org/10.1093/rheumatology/kev257.